)
Boris Minev
President, Medical and Scientific Affairs,
Calidi Biotherapeutics, Inc.
Dr. Boris Minev is a physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development. Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing translational projects on oncolytic virotherapy, immunotherapy and nanotechnology. Dr. Minev is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others.